Developability and CMC at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
36 organizations at Antibody Engineering 2026 present work in developability & CMC: 23 suppliers and service providers, 11 drug developers and 2 academic, government and non-profit bodies. Between them they bring 41 presentations to the program. Most represented: Xencor (4 on the program), Amgen (3 on the program), Johnson & Johnson (3 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–12 of 36 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Chair Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Chair Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Talk Mon Dec 14 5:45pm–6:15pm Induced Proximity and Next-Generation Antibody Therapeutics Bispecifics & multispecifics |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines. | Talk Sun Dec 13 2:15pm–2:45pm Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats. Talk Mon Dec 14 10:55am–11:30am Chair Tue Dec 15 8:10am–8:15am |
Regeneron Tarrytown, NY | |
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform. | Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Beyond oncology Chair Wed Dec 16 8:10am–8:15am |
Twist Bioscience South San Francisco, CA | |
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services. | Booth Exhibiting at Booth 200 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Scaling Wet-Lab Validation for AI-based Biologic Discovery Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it. AI & computational designAntibody discovery Talk Tue Dec 15 1:40pm–2:00pm Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells. Antibody discovery Talk Wed Dec 16 7:30am–8:00am Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC |
University of Michigan Ann Arbor, MI | |
Public research university in Ann Arbor, Michigan. | Chair Sun Dec 13 1:00pm–1:15pm Talk Tue Dec 15 3:00pm–3:30pm Dual-targeted Oligoshuttles Mediate Efficient Reduction of Neuronal Gene Expression after Peripheral Administration Antibodies that grab two receptors to cross into the brain and deliver gene-silencing strands into nerve cells. Bispecifics & multispecifics |
Develops multispecific antibody therapeutics and antibody–drug conjugates using its Azymetric bispecific and other protein engineering platforms. | Talk Sun Dec 13 1:45pm–2:15pm Engineering Conditional Co-stimulation: Key Considerations for Developing Next-Generation T Cell Engagers What to get right, from target choice to safety testing, when building T-cell-recruiting antibodies with a built-in second signal. Bispecifics & multispecifics Talk Wed Dec 16 8:45am–9:15am Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability Antibodies that bind three things at once to give T cells an extra activating signal inside solid tumors. Developability & CMC |
Asimov Boston, MA | |
Offers CHO cell line development services built on its CHO Edge expression system and genetic design software for biologics manufacturing. | Booth Exhibiting at Booth 101 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm An AI-Driven Approach to CHO Biologics Production How a platform combining AI and synthetic biology builds high-yield Chinese hamster ovary cell lines for antibodies, including bispecific and multispecific ones. Developability & CMCAI & computational design |
ATUM Newark, CA | |
Provides gene synthesis, protein expression and the Leap-In transposase system for stable cell line development. | Booth Exhibiting at Booth 309 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:15pm–1:45pm Accelerating Lead Generation: An Integrated End-to-End Antibody Discovery and Engineering Pipeline Moving from mouse immunization to humanized antibodies, then testing how well the leads convert into two-target formats, as one quick pipeline. Antibody discovery |
Contract research, development and manufacturing organization in India offering antibody discovery and biologics development and manufacturing. | Booth Exhibiting at Booth 421 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 1:20pm–1:40pm Discover, Express, De-Risk: Accelerating Antibodies from Single B Cells to Lead Candidates Linking single B-cell sorting to fast antibody production and lab tests that flag molecules likely to cause problems during development. Antibody discoveryDevelopability & CMC |
Primrose Bio San Diego, CA | |
Licenses its Pseudomonas-based Pfenex expression technology and provides strain engineering to take protein therapeutics from sequence to a GMP-ready process. | Booth Exhibiting at Booth 305 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:05pm–12:35pm From Hit Selection to Functional Testing: Reducing Expression Bottlenecks in Antibody Discovery Producing antibody fragments earlier in a different host organism, so more hits can actually be purified and tested. Antibody discoveryDevelopability & CMC |
Thomson Instrument Company Oceanside, CA | |
Supplies Optimum Growth shake flasks, well plates and filter vials for transient and stable cell culture and sample preparation. | Booth Exhibiting at Booth 218 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Tips and Tricks in Speeding up Transient HEK293 and Transient/Stable CHO from 96 Well, 24 Well, 6 Well, 125mL-7L Optimum Growth Flasks Practical ways to get more protein out of small-volume cell cultures, from well plates up to multi-liter flasks. Developability & CMC |
Find buyers in developability & CMC
Tell us what you sell and we’ll find the people at organizations working on developability & CMC most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction